Table 1.
Baseline characteristics of the pregnant women assessed for PCR-corrected treatment efficacy
| AL | AAP | AC | AS | ASAQ | ASMQ | ASSP | DP | Q | QC | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 21 (14–45) | 23 (16–38) | 25 (15–43) | 25·5 (14–44) | 22 (15–46) | 22 (15–45) | 22 (15–42) | 21 (15–43) | 22 (16–41) | 25 (15–41) | |
| Parity | 1 (0–10) | 1 (0–8) | 1 (0–9) | 2 (0–9) | 1 (0–8) | 1 (0–10) | 0 (0–5) | 1 (0–9) | 1 (0–8) | 1 (0–7) | |
| Gravidity | 2 (1–13) | 2 (1–9) | 3 (1–13) | 3 (1–11) | 2 (1–10) | 2 (1–13) | 2 (1–8) | 2 (1–12) | 2 (1–12) | 3 (1–9) | |
| Height (cm) | 156·0 (130–184) | 153·0 (124–161) | 152·0 (140–166) | 151·0 (140–167) | 158·0 (132–179) | 156·0 (125–187) | 149·8 (134–186) | 155·0 (125–178) | 153·0 (141–166) | 154·0 | |
| 1st trimester* | 2/1277 (0·2%) | 2/91 (2·2%) | 0/142 | 5/230 (2·2%) | 0/840 | 3/1028 (0·3%) | 1/172 (0·6%) | 7/872 (0·8%) | 6/243 (2·5%) | 1/67 (1·5%) | |
| 2nd trimester* | 876/1277 (69%) | 53/91 (58%) | 54/142 (38%) | 122/230 (53%) | 624/840 (74%) | 666/1028 (65%) | 122/172 (71%) | 592/872 (68%) | 176/243 (72%) | 40/67 (60%) | |
| 3rd trimester* | 399/1277 (31%) | 36/91 (40%) | 88/142 (62%) | 103/230 (45%) | 216/840 (26%) | 359/1028 (35%) | 49/172 (29%) | 273/872 (31%) | 61/243 (25%) | 26/67 (39%) | |
| Haemoglobin (g/dL) | 10·2 (4·1–15·0) | 9·3 (6·2–12·5) | 9·4 (5·5–13·9) | 9·4 (5·1–13·4) | 10·1 (5·3–15·0) | 9·9 (4·6–14·3) | 9·2 (7·0–14·0) | 10·0 (4·8–15·0) | 10·1 (5·9–14·4) | 9·3 (3·6–12·6) | |
| Weight (kg) | 53 (34–88) | 49 (39–69) | 51 (38–67) | 49 (37–74) | 55 (40–107) | 53 (33–98) | 48 (31–65) | 54 (35–115) | 52 (30–98) | 49 (40–64) | |
| Fever* | 119/1232 (9·7%) | 23/91 (25·3%) | 26/133 (19·5%) | 55/228 (24·1%) | 52/841 (6·2%) | 97/1027 (9·4%) | 31/121 (25·6%) | 42/871 (4·8%) | 46/243 (18·9%) | 13/67 (19·4%) | |
| Parasitaemia (log10/μL) | 3·1 (0–5·7) | 3·6 (1·5–5·5) | 3·3 (1·2–5·5) | 3·4 (1·2–5·5) | 2·8 (1·2–5·0) | 3·0 (1·2–5·4) | 3·3 (1·5–5·3) | 2·9 (0·7–5·6) | 3·3 (1·6–5·3) | 3·3 (1·2–5·0) | |
| Gametocytaemia* | 54/1242 (4·3%) | 4/91 (4·4%) | 18/141 (12·8%) | 21/225 (9·3%) | 24/815 (2·9%) | 17/1007 (1·7%) | 4/122 (3·3%) | 32/874 (3·7%) | 18/243 (7·4%) | 5/66 (7·6%) | |
| Pf mono-infection* | 1265/1278 (99·0%) | 90/91 (98·9%) | 133/142 (93·7%) | 214/230 (93·0%) | 841/841 (100·0%) | 1028/1028 (100·0%) | 173/173 (100·0%) | 864/874 (98·9%) | 243/244 (99·6%) | 63/67 (94·0%) | |
| Malaria transmission* | |||||||||||
| Low | 200/1278 (15·6%) | 91/91 (100·0%) | 141/142 (99·3%) | 230/230 (100·0%) | 26/841 (3·1%) | 188/1028 (18·3%) | 122/173 (70·5%) | 82/874 (9·4%) | 172/244 (70·5%) | 67/67 (100·0%) | |
| Moderate | 776/1278 (60·7%) | 0 | 1/142 (0·7%) | 0 | 482/841 (57·3%) | 507/1028 (49·3%) | 18/173 (10·4%) | 738/874 (84·4%) | 72/244 (29·5%) | 0 | |
| High | 302/1278 (23·6%) | 0 | 0 | 0 | 333/841 (39·6%) | 333/1028 (32·4%) | 33/173 (19·1%) | 54/874 (6·2%) | 0 | 0 | |
Fever is defined as body temperature >37·5°C. Trimesters are categorised as follows: first (≤13 weeks), second (14–27 weeks), and third (≥28 weeks). AAP=artesunate with atovaquone-proguanil. AC=artesunate with clindamycin. AL=artemether-lumefantrine. AS=artesunate monotherapy. ASAQ=artesunate-amodiaquine. ASMQ=artesunate-mefloquine. ASSP=artesunate-sulfadoxine-pyrimethamine. DP=dihydroartemisinin-piperaquine. Pf=Plasmodium falciparum. Q=quinine monotherapy. QC=quinine with clindamycin.
*
Data are presented as the number in the category divided by total number assessed.